市场调查报告书
商品编码
1157567
脑膜炎疫苗的全球市场:至2030年的预测Meningococcal Vaccines market research report - Forecast till 2030 |
全球脑膜炎疫苗的市场规模,预计在检讨期间中以7.29%的年复合成长率发展,到2030年末达59亿1000万美元。牵引市场的主要原因,是疫苗接种受到高度的关注,及抗体革新的研究开发扩大。还有疫苗接种计划,促进市场发展。但,严格的行政规则和审查预计妨碍市场发展。
本报告提供全球脑膜炎疫苗市场相关调查,市场规模和预测,市场动态,各市场区隔的市场分析,竞争情形,主要企业的简介等资讯。
Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.
The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.
The market segmentation of meningococcal immunizations market is as follows
By Vaccine Type
By Serotype
By End-user
North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.
The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.
As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.
The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.
The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS